CA2039477C - Parenterally administrable liposome formulation comprising synthetic lipids - Google Patents
Parenterally administrable liposome formulation comprising synthetic lipids Download PDFInfo
- Publication number
- CA2039477C CA2039477C CA002039477A CA2039477A CA2039477C CA 2039477 C CA2039477 C CA 2039477C CA 002039477 A CA002039477 A CA 002039477A CA 2039477 A CA2039477 A CA 2039477A CA 2039477 C CA2039477 C CA 2039477C
- Authority
- CA
- Canada
- Prior art keywords
- formula
- cis
- synthetic
- pharmaceutical composition
- substantially pure
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Glass Compositions (AREA)
- Paper (AREA)
- Materials For Medical Uses (AREA)
- Manufacturing Of Micro-Capsules (AREA)
- Cosmetics (AREA)
Abstract
The invention relates to pharmaceutical compositions in the form of parenterally, especially intravenously, administrable liposome dispersions or dry preparations, especially lyophilisates, that can be used therefor, comprising the zinc-phthalocyanine complex and synthetic, substantially pure phospholipids.
Description
2Q~~~°~7 4-18022/+
Parenterally administrable liposome formulation com~isino synthetic lipids The invention relates to pharmaceutical compositions in the form of parenterally administrable liposome dispersions, or dry preparations that can be used therefor, comprising the zinc-phthalocyanine complex and synthetic, substantially pure phospholipids, to a novel inventive process for the preparation of those pharmaceutical compositians and to the use of the dry preparations for the preparation of intravenously administrable liposome dispersions and to the use of the zinc-phthalocyanine complex and the synthetic, substantially pure phospholipids for the preparation of dry preparations. The invention relates also to the use of the pharmaceutical compositions in a method for the therapeutic treatment of the human or animal body.
Both the zinc-phthalocyanine complex itself and its therapeutic use in photodynamic chemotherapy for the treatment of tumours are known, see J.D. Spikes, Photochem.
Photobiol. 43, 691 (1986). 'The zinc-phthalocyanine complex is administered intraperitoneally to mice or rats in vivo in the form of an agueous suspension and the carcinoma induced in the experimental animals is irradiated 'with high-energy light, preferably with concentrated visible light (LASER).
The use of intraperitoneal dosage foams in human therapy generally gives rise to problems because of the pain caused by the piercing of the abdominal cavity and the great demands made of the skill of the physician. Attempts are therefore being made to find an alternative parenteral dosage form which is more acceptable to the patient, but which is also capable of ensuring systemic distribution of the zinc-phthalocyanine complex to be administered.
The intravenous dosage form offexs systemic distribution of the active ingredient but requires the active ingredient to be homogeneously distributed in the aqueous injection fluid.
For the preparation of suitable intravenous dosage forms it has therefore been proposed to use instead of the sparingly soluble zinc-phthalocyanine complex the water-soluble ~039~'~~
Parenterally administrable liposome formulation com~isino synthetic lipids The invention relates to pharmaceutical compositions in the form of parenterally administrable liposome dispersions, or dry preparations that can be used therefor, comprising the zinc-phthalocyanine complex and synthetic, substantially pure phospholipids, to a novel inventive process for the preparation of those pharmaceutical compositians and to the use of the dry preparations for the preparation of intravenously administrable liposome dispersions and to the use of the zinc-phthalocyanine complex and the synthetic, substantially pure phospholipids for the preparation of dry preparations. The invention relates also to the use of the pharmaceutical compositions in a method for the therapeutic treatment of the human or animal body.
Both the zinc-phthalocyanine complex itself and its therapeutic use in photodynamic chemotherapy for the treatment of tumours are known, see J.D. Spikes, Photochem.
Photobiol. 43, 691 (1986). 'The zinc-phthalocyanine complex is administered intraperitoneally to mice or rats in vivo in the form of an agueous suspension and the carcinoma induced in the experimental animals is irradiated 'with high-energy light, preferably with concentrated visible light (LASER).
The use of intraperitoneal dosage foams in human therapy generally gives rise to problems because of the pain caused by the piercing of the abdominal cavity and the great demands made of the skill of the physician. Attempts are therefore being made to find an alternative parenteral dosage form which is more acceptable to the patient, but which is also capable of ensuring systemic distribution of the zinc-phthalocyanine complex to be administered.
The intravenous dosage form offexs systemic distribution of the active ingredient but requires the active ingredient to be homogeneously distributed in the aqueous injection fluid.
For the preparation of suitable intravenous dosage forms it has therefore been proposed to use instead of the sparingly soluble zinc-phthalocyanine complex the water-soluble ~039~'~~
derivatives thereof and to administer those derivatives intravenously, see J.
Rousseau et al., Int. J. Appl. Radiat. Isot. 36, 709 (1985).
Although the introduction of hydrophilic groups, such as sulfonyl groups, into the porphyrin nucleus of the zinc-phthalocyanine complex increases the water-solubility of the camplex, the derivatives obtained are of a poor standard and are unsuitable for pharmaceutical use since they consist of non-uniform mixtures of the mono- to tetra-substituted derivatives with several regioisomers, see F.H. Moser et al., The Phthalocyanines, CRC Press, 1983, Vol. II, page 20. The separation of the numerous isomeric derivatives would involve unrealistic expenditure.
As an alternative it has been proposed to solubilise the chemically pure, water-insoluble zinc-phthalocyanine complex in aqueous phase by the addition of a vehicle. For example, using suitable solubilisers in the form of phospholipids, for example di-palmitoylphosphatidyl choline, the complex can be encapsulated in unilamellar liposomes which are substantially homogeneously dispersible in aqueous phase, see E.
Reddi et al., Br. J. Cancer (1987), SG, pages 597-600.
This homogeneous liposome dispersion is nevertheless still unsuitable for the purposes of intravenous administration to humans because the dispersion is prepared in accordance with the so-called injection method using relatively large amounts of toxic pyridine, see G.
Valduga et al., J. Inorg. Biochem. 29, 59-65(1987). Pyridine is one of the few solvents in which the zinc-phthalocyanine complex is at all soluble. That solution is diluted with ethanol and the pyridine-containing ethanolic solution is injected at elevated temperature into water or buffer solution. In accordance with that method a residue of the toxic solvent pyridine will always remain in the aqueous phase as a result of the formation of an azeotropic mixture.
The preparation of liposome dispersions by other methods that do not use organic solvents also gives rise to problems. Even when solvent-free dry preparations, such as lyophili-sates or evaporation residues, are used for the formation of the aqueous liposome dispersions, the preparation of those dry preparations can in turn be effected only from solutions in selected organic solvents or solvent mixtures because of the lipophilic nature and the water-insolubility of the lipid components. Both the zinc-phthalocyanine complex and the phospholipids used have to be completely soluble in those solvents.
The evaporation of the solvents must result in a homogeneous and pourable powder.
The components must not be allowed to separate, as this would result in the agglutination of the dry preparation and the formation not of liposomes but only of poorly dispersible aggregates, for example large micelles, which could cause embolisms.
The problem underlying the present invention is to prepare a parenterally, especially intravenously, administrable liposome dispersion using those solvents in which the zinc-phthalocyanine complex and the phospholipid components are completely soluble and of which the residual amount consisting of unremovable solvent residues is less than 1 %, which amount is toxicologically harmless for intravenous formulations.
The invention relates to pharmaceutical compositions in the form of parenterally administrable liposome dispersions comprising (a) a zinc-phthalocyanine complex of formula ~N 1 N N
N~ \Zri~ \N
-N~ N
~N
i (b) a synthetic, substantially pure phospholipid of formula 3a Ra +/
3CH2-O P (CnH2n) N Rb (I) O- Rc wherein R1 is Clo-Czoalkanoyl having an even number of carbon atoms, Rz is Clo-Czoalkenoyl having an even number of carbon atoms, Ra, Rb and R~ are hydrogen or Cl-C4alkyl and n is an integer from two to four, optionally combined with a c) synthetic, substantially pure phospholipid of formula (S) (II) 3CH2- O p (CnH2n) CH C OH
O NH2 Y+
wherein R3 and R4 are each independently of the other Clo-Czoalkenoyl having an even number of carbon atoms, n is an integer from one to three and Y+ is the cation of a ~~9~~""~
_4_ pharmaceutically acceptable base, and d) a pharmaceutically acceptable carrier liquid and, optionally, water-soluble excipients suitable for parenteral dosage forms.
The terms and definitions used hereinabove and hereinbelow preferably have the following meanings in the context of the description of the invention:
The term "pharmaceutical composition" defines a mixture of substances that is suitable for parenteral administration, in the present case especially for intravenous administration, to humans and animals, preferably to humans, and that can be used for the treatment of various diseases, in the present case tumours.
The parenterally administrable liposome dispersion comprises liposomes in the form of unilamellar, multilamellar, large and small liposomes cansisting of a double-layer arrangement of phospholipids (I) and optionally (II) having an interior space and a spherical shape (unilamellar) or consisting of several concentric double-layer arrangements of phospholipids (I) and optionally (II) having an interior space and a spherical shape ("onion-skin" structure of the double layers or membranes -multilamellar). The size of the liposomes varies from approximately 1.0 x 10'8 to approximately 1.0 x 10-5 m, depending upon the preparation process.
The therapeutic use of liposomes as carriers of active ingredients of different kinds is known. For example, liposomes have been proposed as carriers of proteins, for example antibodies or enzymes> hormones, vitamins or genes, or, for analytical purposes, as carriers of labelled compounds.
Pharmaceutical dosage forms based on liposomes are described in the synoptical work by Gregoriadis G. (Ed.) Liposome Technology, Col. II, Incorporation of Drugs, Proteins and Genetic Material, CRC Press 1984. In the synoptical work by Knight, C.G.
(Ed.), Liposomes: From Physical Structure to Therapeutic Applications, Elsevier 1981, the advantages of a pharmaceutical dosage form based on liposomes are summarised in Chapter 16, page 166.
The liposome dispersion according to the present invention is free of solid particles and larger lipid aggregates, is stable to storage even at room temperature for several days to weeks, is reproducible as regards the proportion of the components, is toxicologically harmless as regards the lipid components used and the residual amounts of organic solvents, and on the basis of findings in vitro and in vivo is suitable for parenteral, especially intravenous, administration to humans.
5 Unless expressly defined otherwise, the term "lower" used in connection with organic radicals, for example lower alkyl, lower alkylene, lower alkoxy, lower alkanoyl etc., indicates that the organic radicals so designated contain up to and including 7, and preferably up to and including 4, carbon atoms.
The nomenclature for the phospholipids of formulae I and II and the numbering of the carbon atoms is in accordance with the recommendations made in the Eur. J. of Biochem. 79, 11-21 (1977) "Nomenclature of Lipids" by the IUPAC-IUB Commission on Biochemical Nomenclature (CBN) (sn-nomenclature, stereospecific numbering).
The zinc-phthalocyanine complex a) corresponds to the compound described on page 1 of the publication by G.
Valduga et al., Photochem. and Photobiology Vol. 48, No. 1 (1988), pages 1-5, which compound has been known for a long time. The structure of this zinc-phthalocyanine complex is:
~N
N N
N~ \Zn~ \N
-N~ N
~N
i 5a The purity of the synthetic phospholipids of formulae I and II is more than 90 %, but preferably more than 95 %, by weight.
This degree of purity can be demonstrated by known analytical methods, for example by chromatography, such as HPLC, gas chromatography or paper chromatography.
In a phospholipid of formula I, R1 as "Clo-C2oalkanoyl having an even number of carbon atoms" is preferably n-dodecanoyl, n-tetradecanoyl, n-hexadecanoyl, n-octadecanoyl or n-icosanoyl.
In a phospholipid of formula I, R2 as "Clo-C2oalkenoyl having an even number of carbon atoms" is preferably 9-cis-dodecenoyl, 9-cis-tetradecenoyl, 9-cis-hexadecenoyl, 6-cis-octadecenoyl, 6-trans-octadecenoyl, 9-cis-octadecenoyl, 9-trans-octadecenoyl, 11-cis-octadecenoyl or 9-cis-icosenoyl.
In a phospholipid of formula I, Ra, Rb and R~ are preferably C1-C4alkyl, especially methyl.
In a phospholipid of formula I, n is an integer from two to four, preferably two. The group ~~3~~"~~
of the formula -(Cnl-I2")- is unbranched or branched alkylene, for example 1,1-ethylene>
1,1-, 1,2- or 1,3-propylene or 1,2-, 1,3- or 1,4-butylene. 1,2-ethylene (n=2) is preferred.
In an especially preferred phospholipid of formula I, Rl is n-dodecanoyl, n-tetradecanoyl, n-hexadecanoyl ar n-octadecanoyl and RZ is 9-cis-dodecenoyl, 9-cis-tetradecenoyl, 9-cis-hexadecenoyl, 9-cis-octadecenoyl or 9-cis-icosenayl, Ra, Rb and R~ are methyl and n is two.
A very especially preferred phospholipid of formula I is synthetic 1-n-hexadecanoyl-2-(9-cis-octadecenoyl)-3-sn-phosphatidyl choline having a purity of more than 90 %, but preferably more than 95 %.
In a phospholipid of formula II, R3 and R4 are as defined for Rl and RZ under formula I.
In a phospholipid of formula II, R3 and R4 as "Clo-CZOalkenoyl having an even number of carbon atoms" are preferably 9-ci.s-dodecenoyl, 9-cis-tetradecenoyl, 9-cis-hexadecenoyl, 6-cis-actadecenoyl, 6-traps-octadecenoyl, 9-cis-octadecenoyl, 9-traps-octadecenoyl, 11-cis-octadecenoyl or 9-cis-icosenoyl.
The cation Ym of a pharmaceutically acceptable base is, for example, an alkali metal ion, for example the lithium, sodium or potassium ion, the ammonium ion, a mono-, di- or tri-Ct-C4alkylammonium ion, for example the trimethyl-, ethyl-, diethyl- or triethyl-ammonium ion, the tetramethylammonium ion, a 2-hydroxyethyi-tri-Ct-C4alkyl-ammonium ion, for example the choline cation, or the 2-hydroxyethylammonium ion, or the cation of a basic amino acid, for example lysine or arginine.
Ym is preferably the sodium ion.
In an especially preferred phospholipid of formula II, R3 and R4 are identical and are, for example, 9-cis-dodecenoyl, 9-cis-tetradecenoyl, 9-cis-hexadecenoyl, 9-cis-octadecenoyl or 9-cis-icosenoyl, n is one and Y~ is the sodium ion.
A very especially preferred phospholipid of formula II is synthetic sodium 1,2-di(9-cis-octadecenoyl)-3-sn-phosphatidyl S-serine having a purity of more than 90 %, but preferably more than 95 %.
The names given in pwenthesis are also customary for the aryl radicals in the phospholipids of formulae I and II:
9-cis-dodecenoyl (lauroleoyl), 9-cis-tetradecenoyl (myristoleoyl), 9-cis-hexadecenoyl (palmitoleoyl), 6-cis-octadecenoyl (petroseloyl), 6-traps-octadecenoyl (petroselaidoyl), 9-cis-octadecenoyl (oleoyl), 9-traps-octadecenoyl (elaidoyl), 11-cis-octadecenoyl (vaccenoyl), 9-cis-icosenoyl (gadoleoyl), n-dodecanoyl (lauroyl), n-tetradecanoyl (myristoyl), n-hexadecanoyl (palmitoyl), n-octadecanoyl (stearoyl), n-icosanoyl (arachidoyl).
In the pharmaceutically acceptable carrier liquid d) the components a) and b) or a), b) and c) are present in the form of liposomes, preferably multilamellar liposomes, in such a manner that for several days or weeks there is no re-formation of solids or solid aggregates, such as micelles, and the clear or in some cases slightly opalescent liquid comprising the said components can be administered, if necessary after filtration, parenterally, preferably intravenously.
The carrier liquid d) may comprise, for example, pharmaceutically acceptable, non-toxic water-soluble excipients that are necessary for the establishment of isotonic conditions, for example ionic additives, such as sodium chloride or non-ionic additives (structure formers), such as sorbitol, mannitol, glucose or lactose. In particular, the dry preparation comprises those additives, for example sodium chloride or mannitol, in the prescribed amounts, which are necessary for the establishment of isotonic conditions in the parenterally administrable solutions.
Suitable water-soluble excipients in the solution and in the dry preparation are also wetting agents or surfactants in the true sense that can be used for liquid pharmaceutical formulations, especially non-ionic surfactants of the fatty acid polyhydroxy alcohol ester type, such as sorbitan monolaurate, monooleate, monostearate or monopalmitate, sorbitan tristearate or trioleate, polyoxyethylene adducts of fatty acid polyhydroxy alcohol esters, such as polyoxyethylene sorbitan monolaurate, monooleate,~monostearate, monopalmitate, txistearate or trioleate, polyethylene glycol fatty acid esters, such as polyoxyethyl stearate, polyethylene glycol 400 stearate, polyethylene glycol X000 stearate, especially ethylene oxide/propylene oxide block polymers of the Pluronic~ type (Wyandotte Chem.
Corp.) or Synperonic~ type (ICI).
The liposome dispersion can be prepared from a dry preparation to which the present _g_ invention likewise relates.
The present invention relates also to pharmaceutical compositions in the form of a dry preparation comprising a) the zinc-phthalocyanine complex, b) a synthetic, substantially pure phospholipid of formula I wherein Rl> R2, Ra, Rb and R
and also n are as defined above, optionally combined with a c) synthetic, substantially pure phospholipid of formula II wherein R3, R4, n and Y~ are as defined above, and optionally d) water-soluble excipients suitable for intravenous dosage forms.
A dry preparation is the residue obtainable after any thermal drying process, such as evaporation at room temperature or elevated temperature or, preferably, freeze-drying, which residue contains less than 1 % (by weight), preferably less than 0.5 %, organic solvent residues, such as piperidine, tent-butanol or dimethyl sulfoxide.
In the dry preparation, the zinc-phthalocyanine complex is present in a ratio of approximately from 0.1 to 5.0 % by weight, preferably from 0.1 to 1.0 % by weight, based on the total amount of phospholipids of formulae I and optionally II -components b) and optionally c). In the dry preparation the mixing ratio of the phospholipids of formula I -the lecithin component - to the phospholipids of formula II - the serine component - is approximately 50:50 % by weight, preferably 70:30 % by weight.
The dry preparation of the present invention is distinguished by good filling properties, exact reproducibility of the weighed amounts introduced into the unit dose forms and storage stability.
The present invention relates also to a process far the preparation of a pharmaceutical composition in the form of a parenterally administrable liposome dispersion, which process comprises dispersing in aqueous phase a dry preparation comprising a) the zinc-phthalocyanine complex, b) a synthetic, substantially pure phospholipid of formula I, wherein Rl, R2, Ra, Rb and R
and also n are as defined above, optionally combined with a c) synthetic, substantially pure phospholipid of formula II, wherein R~, R4, n and Y~ are as defined above, and optionally d) water-soluble excipients suitable for parenteral dosage forms and optionally buffering 20394"~~
the resulting aqueous dispersion to pH 7.0-7.8 andlor isolating a liposome fraction having a desired diameter range, The individual steps of the process are carried out in a manner known per se by reconstituting the dry preparation obtainable in accordance with the invention, prior to administration in the form of a liposome dispersion, in the prescribed amount of liquid, especially in sterile (pyrogen-free) water for injection.
Dispersion is effected, for example, by shaking (for example using a Vortex mixer) or stirring the aqueous phase to which the dry preparation has previously been added. The formation of liposomes, which may be large, small, unilamellar or multilamellar, takes place spontaneously, that is to say without the additional supply of external energy and at great speed. It is possible to disperse approximately from 0.1 to SO % by weight (based on the total weight of the aqueous dispersion), preferably from 2 to 20 % by weight, of the dry preparation in aqueous phase.
Aqueous dispersions having an acidic or basic reaction are preferably buffered to pH
7.0-7.8, preferably pH 7.2-7.4. Optionally dispersion is effected in an aqueous buffer solution that has already been buffered to that pH value.
Dispersion is effected at temperatures of below approximately 36°C, preferably at room temperature. As appropriate, the process is carried out with cooling and/or under an inert gas atmosphere, for example a nitrogen or argon atmosphere. The resulting liposomes are stable in aqueous phase over a very long period (up to several weeks or months).
The size of the liposomes formed depends inter alia upon the amount of active ingredient and the lipid components, the mixing ratio thereof and the concentration of the components in the aqueous dispersion and upon the method of preparation. For example, by increasing or reducing the concentration of lipid components it is possible to produce aqueous phases having a high proportion of small or large liposomes.
It is possible to obtain an especially uniform size distribution of the liposomes by aftertreatment of the liposome dispersion, for example by treatment with ultrasound or extrusion through straight-pored filters (for example Nucleopore~).
The separation and isolation of a fraction of large liposomes from a fraction containing small liposomes, insofar as it is at all necessary, is effected by means of conventional separation methods, for example gel filtration, for example with Sepharose~ 4B
or Sephacryl~ (Pharmacia SE) as carrier, or by sedimentation of the liposomes in an ultracentrifuge, for example with a gravitational field of 160,000 x g. For example, after centrifugation for several hours, for example about three hours, in that gravitational field,large liposomes are deposited, whereas small liposomes remain in dispersion and can be decanted. Repeated centrifugation results in complete separation of the large liposomes from the small liposomes.
Gel filtration especially can be used to separate off all the liposomes present in the aqueous phase having a diameter of more than about 6.0 x 10-s m and also non-encapsulated components and excess, dispersed lipids that are present in high molecular weight aggregates and thus to produce an aqueous dispersion having a fraction of liposomes of relatively uniform size.
The completed formation of liposomes and their content in aqueous phase can be demonstrated in a manner known Rer se by various physical measuring methods, for example with freeze fracture samples and thin sections under an electron microscope or by X-ray diffraction, by dynamic light scattering, by mass determination of the filtrate in an analytical ultracentrifuge and especially by spectroscopy, for example in the nuclear resonance spectrum (1H, 13C and 3tP).
The present invention relates also to a novel, inventive process for the preparation of a pharmaceutical composition in the form of a dry preparation, which process comprises dissolving a) the zinc-phthalocyanine complex and b) a synthetic, substantially pure phospholipid of formula I, whereim Rt, R2, Ra, Rb and R~
and also n are as defined above, optionally combined with a c) synthetic, substantially pure phospholipid of formula II, wherein R3, R4, n and 'lr~ are as defined above, in a pharmaceutically acceptable organic solvent, the residual amount of which in a dry preparation is toxicologically harmless, and optionally d) adding carrier liquid and water-soluble excipients suitable for parenteral dosage forms, and removing the solvent or solvent mixture.
A pharmaceutically acceptable organic solvent, the residual amount of which in a dry preptrration is toxicologically harmless, is suitable for the preparation of a clear solution of the zinc-phthalocyanine complex and if possible the phospholipid components (I) and (II).
If the phospholipids are insoluble in the organic solvent in which the zinc-phthalocyanine complex is soluble, they are dissolved in a second solvent, for example in tort-butanol, and that solution is combined with the solution of the zinc-phthalocyanine complex.
Preferred organic solvents that meet the toxicological requirements as regards the residual amounts present in the dry preparation and in which the zinc-phthalocyanine complex is soluble are dimethyl sulfoxide, N-methyl-2-pyrrolidone and piperidine, and mixtures thereof.
The zinc-phthalocyanine complex is soluble in dimethyl sulfoxide and N-methyl-2-pyrrolidone (NMP) but the phospholipids (I) and (II) are not. Both the zinc-phthalocyanine complex and the phospholipids (I) and (II) are soluble in piperidine. All solvents are toxicologically harmless in the residual amounts of less than 1 %, preferably less than 0.5 °lo, present in the dry preparation.
When dimethyl sulfoxide or NMP is used, the zinc-phthalocyanine complex is dissolved in the minimum necessary amount of that solvent and the solution is combined with a second solution of the phospholipids that is miscible with the first solution of the zinc-phthalocyanine complex. In addition to the requirement of being miscible with the dimethyl sulfoxide solution, this second solvent is subject to the same toxicological requirements as regards the residual amounts present in the dry preparation.
Such a suitable solvent in which the phospholipids (I) and (1I) are completely soluble is,,for example, tert-butanol.
The preparation of the dry preparation, preferably a lyophilisate, can be effected by modifying known methods, by first dissolving the introduced amount of the phospholipid, for example 1-hexadecanoyl-2-(9-cis-octadecenoyl)-3-sn-phosphatidyl choline, if required with gentle heating, in the amount of tert-butanol required for the dissolution process and combining that clear solution with a second solution comprising a defined amount of the zinc-phthalocyanine complex in an amount of dimethyl sulfoxide or NMP
appropriate for the dissolution process. Alternatively, it is possible to dissolve the phospholipids (I) and (II) at approximately from 0°C to roam temperature, preferably at 0°C, and the zinc-phthalocyanine complex at from room temperature to approximately 40°C, preferably room temperature, in the minimum necessary amount of piperidine or in piperidine containing up to about 10 %, preferably abaut 2 to 3 %, water and to remove the solvent from that clear solution in order to produce the dry preparation. The clear solution in the said organic solvents can then be combined with the carrier liquid d) comprising water-soluble excipients, especially non-ionic additives such as lactose. The dry preparation can be prepared by removing the solvent mixture at low temperature below about 0°C (lyophilisation) or at normal or elevated temperature (film formation). The solvent mixture used for the preparation of the dry preparation can also be dialysed for the purpose of purification and the dialysed aqueous solution, which contains no organic solvent, concentrated by ultrafiltration. The dry preparation is then prepared by removing water, preferably by lyophilisation. Measured amounts of the solution to be lyophilised can be introduced into suitable containers for a unit dose, such as ampoules, for example glass phials. The filled containers can then be frozen at about -40° to -50°C, especially at -45°C, and then lyophilised at a pressure of about 0.2-0.6 mbar by slowly heating to a final temperature of about 25°-35°C.
The solvent or solvent mixture comprising components a), b) and c) can be converted into a dry preparation also directly, without cooling, thermally in a larger vessel (film formation method). Freeze-drying from small vessels containing a unit dose is preferred, however, as this method avoids the operation of filling the dry preparation itself and therefore allows the accurate apportionment of unit doses from liquids.
Surprisingly, it has been possible using the said processes to prepare, reproducibly, dry preparations, especially lyophilisates, and liposome dispersions reconstitutable therefrom, that are st<lble and suitable for injection.
The present invention relates also to the use of the dry preparation obtainable in accordance with the said processes for the preparation of intravenously administrable liposome dispersions.
The present invention relates also to the use of the zinc-phthalocyanine complex and the phospholipid components of formula I and optionally of formula II for the preparation of dry preparations, especially lyophilisates, in accordance with the methods described hereinabove. The invention relates also to the use of the pharmaceutical compositions in a method for the therapeutic treatment of the human or animal body, especially in chemotherapy for the treatment of tumours. The liposome dispersion is administered parenterally, especially intravenously, and the carcinoma is irradiated with high-energy light, preferably with concentrated visible light (LASER).
The invention relates preferably to pharmaceutical compositions in the form of intravenously administrable liposome dispersions comprising a) the zinc-phthalocyanine complex, b) a synthetic, substantially pure phospholipid of formula I, wherein R1 is n-dodecanoyl, n-tetradecanoyl, n-hexadecanoyl or n-octadecanoyl and R2 is 9-cis-dodecenoyl, 9-cis-tetradecenoyl, 9-cis-hexadecenoyl, 9-cis-octadecenoyl or 9-cis-icosenoyl, Ra, Rb and R
are methyl and n is two, optionally combined with a c) synthetic, substantially pure phospholipid of formula II, wherein R3 and R4 are identical and are 9-cis-dodecenoyl, 9-cis-tetradecenoyl, 9-cis-hexadecenoyl, 9-cis-octadecenoyl or 9-cis-icosenoyl, n is one and Y~ is the sodium ion, and d) a pharmaceutically acceptable carrier liquid and, optionally, water-soluble excipients suitable for intravenous dosage forms.
The invention relates preferably also to pharmaceutical compositions in the form of dry preparations comprising the said preferred components a), b), optionally combined with c), and d) water-soluble excipients suitable for intravenous dosage forms.
The invention relates especially to pharmaceutical compositions in the form of intravenously administrable liposome dispersions comprising a) the zinc-phthalocyanine complex, b) synthetic, substantially pure 1-n-hexadecanoyl-2-(9-cis-octadecenoyl)-3-sn-phosphatidyl choline (I), optionally combined with c) synthetic, substantially pure sodium 1,2-di(9-cis-octadecenoyl)-3-sn-phosphatidyl S-serine (II), and d) a pharmaceutically acceptable carrier liquid and, optionally, water-soluble excipients suitable for intravenous dosage forms.
The invention relates especially preferably to pharmaceutical compositions in the form of lyophilisates comprising a) the zinc-phthalocyanine complex, b) synthetic, substantially pure 1-n-hexadecanoyl-2-(9-cis-octadecenoyl)-3-sn-phosphatidyl choline (I), optionally combined with c) synthetic, substantially pure sodium 1,2-di(9-cis-octadecenoyl)-3-sn-phosphatidyl S-serine (II), and d) water-soluble excipients suitable for intravenous dosage forms.
~03~4~'~
The invention relates especially to pharmaceutical compositions in the form of intravenously administrable liposome dispersions comprising a) the zinc-phthalocyanine complex, b) approximately 70 °l° by weight (based on component c)) synthetic, substantially pure 1-n-hexadecanoyl-2-(9-cis-octadecenoyl)-3-sn-phosphatidyl choline (I), combined with c) approximately 30 % by weight (based on component b)) synthetic, substantially pure sodium 1,2-di(9-cis-octadecenoyl)-3-sn-phosphatidyl S-serine (II), and d) a pharmaceutically acceptable carrier liquid and, optionally, water-soluble excipients suitable for intravenous dosage forms.
The invention .relates especially also to pharmaceutical compositions in the form of lyophilisates comprising:
a) the zinc-phthalocyanine complex, b) approximately 70 °l° by weight (based on component c)) synthetic, substantially pure 1-n-hexadecanoyl-2-(9-cis-octadecenoyl)-3-sn-phosphatidyl choline (I), combined with c) approximately 30 °l° by weight (based on component b)) synthetic, substantially pure sodium 1,2-di(9-cis-actadecenoyl)-3-sn-phosphatidyl S-serine (II), and d) water-soluble excipients suitable for intravenous dosage forms.
The following Examples illustrate the invention.
Exam-ale 1: 1 mg of zinc-phthalocyanine, 70 mg of at least 95 °lo pure 1-n-hexadecanoyl-2-(9-cis-octadecenoyl)-3-sn-phosphatidyl choline and 30 mg of at least 95 °l° pure 1,2-di-(9-cis-octadecenoyl)-3-sn-phasphatidyl serine are dissolved in 2 ml of piperidine in a round-bottomed flask. The solution is sterile-filtered using an ACRODISC
membrane filter (2.2 x 10-~ m) and the clear solution is introduced into phials.
After the solution has been frozen at -40°C, the phials are dried in vacuo until a temperature of 25°C has been reached and are sealed under an argon atmosphere.
Before use, 1.5 ml of sterile, calcium- and magnesium-free, phosphate-buffered (pI-I
7.2-7.4) sodium chloride solution (Dulbecco) are introduced into the above-mentioned dry preparation (lyophilisate) at room temperature using a sterile syringe and the phials are shaken for one minute on a standard laboratory shaker (Vortex, stage 7). The resulting liposome dispersion can be stored at 4°C and is suitable for intravenous administration.
Example 2: Depending upon the batch, from 0.1 to 1 mg of zinc-phthalocyanine and from 15 to 400 mg of a 7:3 mixture by weight of 95 to 100 % pure 1-n-hexadecanoyl-2-(9-cis-octadecenoyl)-3-sn-phosphatidyl choline and 95 to 100 % pure 1,2-di(9-cis-octadecenoyl)-3-sn-phosphatidyl serine are dissolved in 2 ml of piperidine in a round-bottomed flask. The solution is sterile-filtered using an ACRODISC
membrane filter (2.2 x 10-~) and the clear solution is introduced into phials.
The phials are set in rotation at 150 rpm and the solvent is blown off in a stream of purified nitrogen filtered at 1 bar.
The phials are then evacuated in a vacuum of 6.0 x 10-2 bar. The phials are sealed under an argon atmosphere. Before use, 1.5 ml of sterile, calcium- and magnesium-free, phosphate-buffered (pH 7.2-7.4) sodium chloride solution (Dulbecco) are added to the above-prepared film at room temperature using a syringe and the phials are shaken for 10 minutes on a standard laboratory shaker (stage 7). The resulting liposome dispersion can be stored at 4°C and is suitable for intravenous administration.
Example 3: In a manner analogous to Example 1, after being frozen the solutions mentioned in Example 2 are dried in vacuo and lyophilisates are prepared.
Example 4: In a manner analogous to Examples 2 and 3 it is also possible to prepare solutions comprising from 5:5 to 9:1 mixtures by weight of 1-n-hexadecanoyl-2-(9-cis-octadecenoyl)-3-sn-phosphatidyl choline and 1,2-di(9-cis-octadecenoyl)-phosphatidyl serine.
Example 5: 125 ml of 95 % pure 1-n-hexadecanoyl-2-(9-cis-octadecenoyl)-3-sn-phosphatidyl choline (Avanti, Polar Lipids) are dissolved in 0.5 ml of tert-butanol in a round-bottomed flask. 0.05 mg of zinc-phthalocyanine is dissolved separately in 0.5 ml of sterile dimethyl sulfoxide in a second round-bottomed flask.
The two solutions are combined and sterile-filtered through an ACRODISC
membrane filter (2.2 x 10-~ m). After the introduction of the clear solution into a phial, it is frozen at -80°C. The phials are dried ip vacuo until a temperature of 25°C
has been reached and are sealed under an argon atmosphere.
The further process steps are carried out analogously to Example 1.
Example 6: 12.5 to 25 mg of 95 °lo pure 1-n-hexadecanoyl-2-(9-cis-octadecenoyl)-3-sn-phosphatidyl choline (Avanti, Folar Lipids) are dissolved in 0.5 ml of tert-butanol in a round-bottomed flask. 0.05 mg of zinc-phthalocyanine is dissolved separately in 0.5 ml of sterile dimethyl sulfoxide in a second round-bottomed flask.
Analogously to Example S the two solutions are combined, sterile-filtered using an ACRODISC and introduced into phials. The phials are set in rotation at 150 rpm and the solvent is blown aff in a stream of purified nitrogen filtered at 1 bar. The phials are then evacuated under a pure vacuum of 6.0 x 10-2 bar. The phials are sealed under a protective argon atmosphere.
The further process steps are carried out analogously to Example 2.
Example 7: 0.5 mg of zinc-phthalocyanine and 250 mg of 95 °lo pure 1-n-hexadecenoyl-2-(9-cis-octadecanoyl)-3-sn-phosphatidyl choline are dissolved in 1 ml of sterile piperidine in a round-bottomed flask. The solution is sterile-filtered using an ACRODISC
membrane filter (2.2 x 10-7 m) and the clear solution is introduced into phials.
Analogously to Example 5 it is possible to produce a lyophilisate or, if desired, a film residue analogously to Example 6, which is then converted into an intravenously administrable liposome dispersion analogously to Example 1 or 2.
Example $: In a manner analogous to Example 7 it is possible to produce a lyophilisate or a film residue by dissolving 3 mg of zinc-phthalocyanine in 1 ml of sterile piperidine.
From these dry preparations there is then produced an intravenously administrable lipasome dispersion analogously to Example 1 or 2.
Example 9: In a measuring flask at room temperature, depending upon the batch 200-400 mg of zinc-phthalocyanine are dissolved in 400 ml of piperidine puriss. and the solution is made up to 500 ml. In a second flask at room temperature, depending upon the batch 120-240 mg of a 7:3 mixture by weight of 95-100 °!o pure 1-n-hexadecanoyl-2-(9-cis-octadecenoyl)-3-sn-phosphatidyl choline and 95-100 % pure 1,2-di(9-cis-octadecenoyl)-3-sn-phosphatidyl S-serine are dissolved in 6 ml of piperidine puriss., and 6-12 ml of the above zinc-phthalocyanine solution are added. The resulting solution is ~~3~4'~~
sterile-filtered using an ACRODISC membrane filter (2.2 x 10-~) and the clear solution is introduced into phials.
The further process steps are carried aut analogously to Example 1.
Example 10: In a measuring flask at room temperature, depending upon the batch 200-400 mg of zinc-phthalocyanine are dissolved in 400 ml of piperidine puriss. and the solution is made up to 500 ml. In a second flask, depending upon the batch 120-240 mg' of a 7:3 mixture by weight.of 95-100 % pure 1-n-hexadecanoyl-2-(9-cis-octadecenoyl)-3-sn-phosphatidyl choline and 95-100 % pure 1,2-di(9-cis-octadecenoyl)-3-sn-phosphatidyl S-serine are dissolved in 6 ml of a piperidine/water mixture (2-10 %) at 0-4°C and at that temperature 6-12 ml of the above zinc-phthalocyanine solution are added dropwise thereto. The resulting solution is sterile-filtered using an ACRODISC
membrane filter (2.2 x 10- ) and the clear solution is introduced into phials.
The further process steps are carried out analogously to Example 2.
Example 11: After sterile-filtration, a solution of zinc-phthalocyanine and lipid mixture prepared according to Example 9 or Example 10 is not introduced into phials but is lyophilised in a batch process. Aliquot amounts of the resulting lyophilisate are converted into a liposome dispersion analogously to Example 1.
Example 12: 100 mg of zinc-phthalocyanine, 7000 mg of 95 % pure 1-n-hexadecanoyl-2-(9-cis-octadecanoyl)-3-sn-phosphatidyl choline (POPC) and 3000 mg of 95 % pure sodium 1,2-di(9-cis-octadecanoyl)-3-sn-phosphatidyl S-serine (OOPS) are dissolved in 205 ml of freshly distilled piperidine in a round-bottomed flask.
To that solution there are added, with stirring, 2000 ml of 9.75 % W/V aqueous lactose solution. After the pII value has been adjusted to 7.0 by the addition of dilute HCl, the resulting dispersion is concentrated to a concentration of 0.5 mg of zinc-phthalocyanine/ml and dialysed against 2000 ml of 9.75 % lactose using a Millipore Minitan~ tangential dialysis apparatus.
The resulting lactose-containing dispersion is then sterile-filtered using an ACRODISC
membrane filter (2.2 x 10- ) and introduced into phials (2 ml per phial containing 1 mg of zinc-phthalocyanine). After the dispersion has been frozen at -4U°C, the phials are dried in vacuo until a temperature of 25°C has been reached and are sealed under an argon atmosphere.
The resulting dry preparations can be stored at 4°C for several years.
Before administration, 2.0 ml of water are injected using a sterile syringe into a dry preparation (lyophilisate) in a phial at room temperature. After a maximum dissolution time of one minute there is formed a liposome dispersion suitable fox intravenous administration.
Example 13: In a manner analogous to Example 12, it is possible to carry out the process with 10 000 mg of POPC.
Example 14: In a manner analogous to Example 13, it is possible to carry out the process with 300 mg of POPC or 210 mg of POPC and 90 mg of OOPS.
Example 15: In a flask, 35 g of POPC and 15 g of OOPS are dissolved in 500 ml of tertiary butanol, with stirring, at 40°C. In a further flask, 0.'i g of zinc-phthalocyanine is dissolved in 125 ml of NMP (ultrasonic bath).
The two solutions are mixed together, the dye solution being poured into the tertiary butanol solution. The mixture is heated to 40°C in order to obtain a clear solution. Using a dynamic mixer, that solution is mixed with 10 litres of lactose medium that has been cooled to 4°C and that contains per litre 94.9 g of lactose for injection and 24 g of sodium chloride.
The organic phase is pumped at a rate of 107 ml/min and the lactose solution at a rate of 1714 ml/min into the dynamic mixer, which is operated at a pressure of 3 bar.
The resulting blue, slightly opalescent dispersion (10625 ml) is concentrated to 1 litre and then dialysed against 10 litres of lactose medium using a Millipore tmgential dialysis .
apparatus.
The further procedure is described in Example 12.
Example 16: In a manner analogous to Example 15, 3.5 g of POPC and 1.5 g of OOPS are dissolved in 100 ml of tort-butanol and mixed with 25 ml of NMP and 100 mg of zinc-phthalocyanine. The organic phase is then mixed with 2 litres of lactose medium (25 g of lactose and 0.064 g of NaCI per litre). The dialysis medium has the same composition.
Example 17: In a manner analogous to Example 16; the organic phase is mixed with 2 litres of lactose medium containing 50 g of lactose and 0.127 g of NaCl per litre.
Example 18: In a manner analogous to Example 15, I0.5 g of POPC and 4.5 g of OOPS' are dissolved in 200 ml of tort-butanol and mixed with 50 ml of NMP containing 200 mg of zinc-phthalocyanine. The organic phase is mixed with 4 litres of lactose medium containing 37.5 g of lactose and 0.095 g of NaCI per litre. The dialysis medium has the same composition.
Exam 1p a 19: In a manner analogous to Example 18, the organic phase is mixed with 4 litres of lactose solution containing 75 g of lactose and 0.1905 g of NaCI
per litre. The dialysis medium has the same composition.
Example 20: In a manner analogous to Example 15, 3.5 g of POPC and 1.5 g of OOPS are dissolved in 200 ml of tert-butanol and mixed with 50 m1 of NMP containing 200 mg of zinc-phthalocyanine. The organic phase is mixed with 4 litres of lactose medium containing 25 g of lactose and 0.064 g of NaCI per litre. The dialysis medium has the same composition.
Rousseau et al., Int. J. Appl. Radiat. Isot. 36, 709 (1985).
Although the introduction of hydrophilic groups, such as sulfonyl groups, into the porphyrin nucleus of the zinc-phthalocyanine complex increases the water-solubility of the camplex, the derivatives obtained are of a poor standard and are unsuitable for pharmaceutical use since they consist of non-uniform mixtures of the mono- to tetra-substituted derivatives with several regioisomers, see F.H. Moser et al., The Phthalocyanines, CRC Press, 1983, Vol. II, page 20. The separation of the numerous isomeric derivatives would involve unrealistic expenditure.
As an alternative it has been proposed to solubilise the chemically pure, water-insoluble zinc-phthalocyanine complex in aqueous phase by the addition of a vehicle. For example, using suitable solubilisers in the form of phospholipids, for example di-palmitoylphosphatidyl choline, the complex can be encapsulated in unilamellar liposomes which are substantially homogeneously dispersible in aqueous phase, see E.
Reddi et al., Br. J. Cancer (1987), SG, pages 597-600.
This homogeneous liposome dispersion is nevertheless still unsuitable for the purposes of intravenous administration to humans because the dispersion is prepared in accordance with the so-called injection method using relatively large amounts of toxic pyridine, see G.
Valduga et al., J. Inorg. Biochem. 29, 59-65(1987). Pyridine is one of the few solvents in which the zinc-phthalocyanine complex is at all soluble. That solution is diluted with ethanol and the pyridine-containing ethanolic solution is injected at elevated temperature into water or buffer solution. In accordance with that method a residue of the toxic solvent pyridine will always remain in the aqueous phase as a result of the formation of an azeotropic mixture.
The preparation of liposome dispersions by other methods that do not use organic solvents also gives rise to problems. Even when solvent-free dry preparations, such as lyophili-sates or evaporation residues, are used for the formation of the aqueous liposome dispersions, the preparation of those dry preparations can in turn be effected only from solutions in selected organic solvents or solvent mixtures because of the lipophilic nature and the water-insolubility of the lipid components. Both the zinc-phthalocyanine complex and the phospholipids used have to be completely soluble in those solvents.
The evaporation of the solvents must result in a homogeneous and pourable powder.
The components must not be allowed to separate, as this would result in the agglutination of the dry preparation and the formation not of liposomes but only of poorly dispersible aggregates, for example large micelles, which could cause embolisms.
The problem underlying the present invention is to prepare a parenterally, especially intravenously, administrable liposome dispersion using those solvents in which the zinc-phthalocyanine complex and the phospholipid components are completely soluble and of which the residual amount consisting of unremovable solvent residues is less than 1 %, which amount is toxicologically harmless for intravenous formulations.
The invention relates to pharmaceutical compositions in the form of parenterally administrable liposome dispersions comprising (a) a zinc-phthalocyanine complex of formula ~N 1 N N
N~ \Zri~ \N
-N~ N
~N
i (b) a synthetic, substantially pure phospholipid of formula 3a Ra +/
3CH2-O P (CnH2n) N Rb (I) O- Rc wherein R1 is Clo-Czoalkanoyl having an even number of carbon atoms, Rz is Clo-Czoalkenoyl having an even number of carbon atoms, Ra, Rb and R~ are hydrogen or Cl-C4alkyl and n is an integer from two to four, optionally combined with a c) synthetic, substantially pure phospholipid of formula (S) (II) 3CH2- O p (CnH2n) CH C OH
O NH2 Y+
wherein R3 and R4 are each independently of the other Clo-Czoalkenoyl having an even number of carbon atoms, n is an integer from one to three and Y+ is the cation of a ~~9~~""~
_4_ pharmaceutically acceptable base, and d) a pharmaceutically acceptable carrier liquid and, optionally, water-soluble excipients suitable for parenteral dosage forms.
The terms and definitions used hereinabove and hereinbelow preferably have the following meanings in the context of the description of the invention:
The term "pharmaceutical composition" defines a mixture of substances that is suitable for parenteral administration, in the present case especially for intravenous administration, to humans and animals, preferably to humans, and that can be used for the treatment of various diseases, in the present case tumours.
The parenterally administrable liposome dispersion comprises liposomes in the form of unilamellar, multilamellar, large and small liposomes cansisting of a double-layer arrangement of phospholipids (I) and optionally (II) having an interior space and a spherical shape (unilamellar) or consisting of several concentric double-layer arrangements of phospholipids (I) and optionally (II) having an interior space and a spherical shape ("onion-skin" structure of the double layers or membranes -multilamellar). The size of the liposomes varies from approximately 1.0 x 10'8 to approximately 1.0 x 10-5 m, depending upon the preparation process.
The therapeutic use of liposomes as carriers of active ingredients of different kinds is known. For example, liposomes have been proposed as carriers of proteins, for example antibodies or enzymes> hormones, vitamins or genes, or, for analytical purposes, as carriers of labelled compounds.
Pharmaceutical dosage forms based on liposomes are described in the synoptical work by Gregoriadis G. (Ed.) Liposome Technology, Col. II, Incorporation of Drugs, Proteins and Genetic Material, CRC Press 1984. In the synoptical work by Knight, C.G.
(Ed.), Liposomes: From Physical Structure to Therapeutic Applications, Elsevier 1981, the advantages of a pharmaceutical dosage form based on liposomes are summarised in Chapter 16, page 166.
The liposome dispersion according to the present invention is free of solid particles and larger lipid aggregates, is stable to storage even at room temperature for several days to weeks, is reproducible as regards the proportion of the components, is toxicologically harmless as regards the lipid components used and the residual amounts of organic solvents, and on the basis of findings in vitro and in vivo is suitable for parenteral, especially intravenous, administration to humans.
5 Unless expressly defined otherwise, the term "lower" used in connection with organic radicals, for example lower alkyl, lower alkylene, lower alkoxy, lower alkanoyl etc., indicates that the organic radicals so designated contain up to and including 7, and preferably up to and including 4, carbon atoms.
The nomenclature for the phospholipids of formulae I and II and the numbering of the carbon atoms is in accordance with the recommendations made in the Eur. J. of Biochem. 79, 11-21 (1977) "Nomenclature of Lipids" by the IUPAC-IUB Commission on Biochemical Nomenclature (CBN) (sn-nomenclature, stereospecific numbering).
The zinc-phthalocyanine complex a) corresponds to the compound described on page 1 of the publication by G.
Valduga et al., Photochem. and Photobiology Vol. 48, No. 1 (1988), pages 1-5, which compound has been known for a long time. The structure of this zinc-phthalocyanine complex is:
~N
N N
N~ \Zn~ \N
-N~ N
~N
i 5a The purity of the synthetic phospholipids of formulae I and II is more than 90 %, but preferably more than 95 %, by weight.
This degree of purity can be demonstrated by known analytical methods, for example by chromatography, such as HPLC, gas chromatography or paper chromatography.
In a phospholipid of formula I, R1 as "Clo-C2oalkanoyl having an even number of carbon atoms" is preferably n-dodecanoyl, n-tetradecanoyl, n-hexadecanoyl, n-octadecanoyl or n-icosanoyl.
In a phospholipid of formula I, R2 as "Clo-C2oalkenoyl having an even number of carbon atoms" is preferably 9-cis-dodecenoyl, 9-cis-tetradecenoyl, 9-cis-hexadecenoyl, 6-cis-octadecenoyl, 6-trans-octadecenoyl, 9-cis-octadecenoyl, 9-trans-octadecenoyl, 11-cis-octadecenoyl or 9-cis-icosenoyl.
In a phospholipid of formula I, Ra, Rb and R~ are preferably C1-C4alkyl, especially methyl.
In a phospholipid of formula I, n is an integer from two to four, preferably two. The group ~~3~~"~~
of the formula -(Cnl-I2")- is unbranched or branched alkylene, for example 1,1-ethylene>
1,1-, 1,2- or 1,3-propylene or 1,2-, 1,3- or 1,4-butylene. 1,2-ethylene (n=2) is preferred.
In an especially preferred phospholipid of formula I, Rl is n-dodecanoyl, n-tetradecanoyl, n-hexadecanoyl ar n-octadecanoyl and RZ is 9-cis-dodecenoyl, 9-cis-tetradecenoyl, 9-cis-hexadecenoyl, 9-cis-octadecenoyl or 9-cis-icosenayl, Ra, Rb and R~ are methyl and n is two.
A very especially preferred phospholipid of formula I is synthetic 1-n-hexadecanoyl-2-(9-cis-octadecenoyl)-3-sn-phosphatidyl choline having a purity of more than 90 %, but preferably more than 95 %.
In a phospholipid of formula II, R3 and R4 are as defined for Rl and RZ under formula I.
In a phospholipid of formula II, R3 and R4 as "Clo-CZOalkenoyl having an even number of carbon atoms" are preferably 9-ci.s-dodecenoyl, 9-cis-tetradecenoyl, 9-cis-hexadecenoyl, 6-cis-actadecenoyl, 6-traps-octadecenoyl, 9-cis-octadecenoyl, 9-traps-octadecenoyl, 11-cis-octadecenoyl or 9-cis-icosenoyl.
The cation Ym of a pharmaceutically acceptable base is, for example, an alkali metal ion, for example the lithium, sodium or potassium ion, the ammonium ion, a mono-, di- or tri-Ct-C4alkylammonium ion, for example the trimethyl-, ethyl-, diethyl- or triethyl-ammonium ion, the tetramethylammonium ion, a 2-hydroxyethyi-tri-Ct-C4alkyl-ammonium ion, for example the choline cation, or the 2-hydroxyethylammonium ion, or the cation of a basic amino acid, for example lysine or arginine.
Ym is preferably the sodium ion.
In an especially preferred phospholipid of formula II, R3 and R4 are identical and are, for example, 9-cis-dodecenoyl, 9-cis-tetradecenoyl, 9-cis-hexadecenoyl, 9-cis-octadecenoyl or 9-cis-icosenoyl, n is one and Y~ is the sodium ion.
A very especially preferred phospholipid of formula II is synthetic sodium 1,2-di(9-cis-octadecenoyl)-3-sn-phosphatidyl S-serine having a purity of more than 90 %, but preferably more than 95 %.
The names given in pwenthesis are also customary for the aryl radicals in the phospholipids of formulae I and II:
9-cis-dodecenoyl (lauroleoyl), 9-cis-tetradecenoyl (myristoleoyl), 9-cis-hexadecenoyl (palmitoleoyl), 6-cis-octadecenoyl (petroseloyl), 6-traps-octadecenoyl (petroselaidoyl), 9-cis-octadecenoyl (oleoyl), 9-traps-octadecenoyl (elaidoyl), 11-cis-octadecenoyl (vaccenoyl), 9-cis-icosenoyl (gadoleoyl), n-dodecanoyl (lauroyl), n-tetradecanoyl (myristoyl), n-hexadecanoyl (palmitoyl), n-octadecanoyl (stearoyl), n-icosanoyl (arachidoyl).
In the pharmaceutically acceptable carrier liquid d) the components a) and b) or a), b) and c) are present in the form of liposomes, preferably multilamellar liposomes, in such a manner that for several days or weeks there is no re-formation of solids or solid aggregates, such as micelles, and the clear or in some cases slightly opalescent liquid comprising the said components can be administered, if necessary after filtration, parenterally, preferably intravenously.
The carrier liquid d) may comprise, for example, pharmaceutically acceptable, non-toxic water-soluble excipients that are necessary for the establishment of isotonic conditions, for example ionic additives, such as sodium chloride or non-ionic additives (structure formers), such as sorbitol, mannitol, glucose or lactose. In particular, the dry preparation comprises those additives, for example sodium chloride or mannitol, in the prescribed amounts, which are necessary for the establishment of isotonic conditions in the parenterally administrable solutions.
Suitable water-soluble excipients in the solution and in the dry preparation are also wetting agents or surfactants in the true sense that can be used for liquid pharmaceutical formulations, especially non-ionic surfactants of the fatty acid polyhydroxy alcohol ester type, such as sorbitan monolaurate, monooleate, monostearate or monopalmitate, sorbitan tristearate or trioleate, polyoxyethylene adducts of fatty acid polyhydroxy alcohol esters, such as polyoxyethylene sorbitan monolaurate, monooleate,~monostearate, monopalmitate, txistearate or trioleate, polyethylene glycol fatty acid esters, such as polyoxyethyl stearate, polyethylene glycol 400 stearate, polyethylene glycol X000 stearate, especially ethylene oxide/propylene oxide block polymers of the Pluronic~ type (Wyandotte Chem.
Corp.) or Synperonic~ type (ICI).
The liposome dispersion can be prepared from a dry preparation to which the present _g_ invention likewise relates.
The present invention relates also to pharmaceutical compositions in the form of a dry preparation comprising a) the zinc-phthalocyanine complex, b) a synthetic, substantially pure phospholipid of formula I wherein Rl> R2, Ra, Rb and R
and also n are as defined above, optionally combined with a c) synthetic, substantially pure phospholipid of formula II wherein R3, R4, n and Y~ are as defined above, and optionally d) water-soluble excipients suitable for intravenous dosage forms.
A dry preparation is the residue obtainable after any thermal drying process, such as evaporation at room temperature or elevated temperature or, preferably, freeze-drying, which residue contains less than 1 % (by weight), preferably less than 0.5 %, organic solvent residues, such as piperidine, tent-butanol or dimethyl sulfoxide.
In the dry preparation, the zinc-phthalocyanine complex is present in a ratio of approximately from 0.1 to 5.0 % by weight, preferably from 0.1 to 1.0 % by weight, based on the total amount of phospholipids of formulae I and optionally II -components b) and optionally c). In the dry preparation the mixing ratio of the phospholipids of formula I -the lecithin component - to the phospholipids of formula II - the serine component - is approximately 50:50 % by weight, preferably 70:30 % by weight.
The dry preparation of the present invention is distinguished by good filling properties, exact reproducibility of the weighed amounts introduced into the unit dose forms and storage stability.
The present invention relates also to a process far the preparation of a pharmaceutical composition in the form of a parenterally administrable liposome dispersion, which process comprises dispersing in aqueous phase a dry preparation comprising a) the zinc-phthalocyanine complex, b) a synthetic, substantially pure phospholipid of formula I, wherein Rl, R2, Ra, Rb and R
and also n are as defined above, optionally combined with a c) synthetic, substantially pure phospholipid of formula II, wherein R~, R4, n and Y~ are as defined above, and optionally d) water-soluble excipients suitable for parenteral dosage forms and optionally buffering 20394"~~
the resulting aqueous dispersion to pH 7.0-7.8 andlor isolating a liposome fraction having a desired diameter range, The individual steps of the process are carried out in a manner known per se by reconstituting the dry preparation obtainable in accordance with the invention, prior to administration in the form of a liposome dispersion, in the prescribed amount of liquid, especially in sterile (pyrogen-free) water for injection.
Dispersion is effected, for example, by shaking (for example using a Vortex mixer) or stirring the aqueous phase to which the dry preparation has previously been added. The formation of liposomes, which may be large, small, unilamellar or multilamellar, takes place spontaneously, that is to say without the additional supply of external energy and at great speed. It is possible to disperse approximately from 0.1 to SO % by weight (based on the total weight of the aqueous dispersion), preferably from 2 to 20 % by weight, of the dry preparation in aqueous phase.
Aqueous dispersions having an acidic or basic reaction are preferably buffered to pH
7.0-7.8, preferably pH 7.2-7.4. Optionally dispersion is effected in an aqueous buffer solution that has already been buffered to that pH value.
Dispersion is effected at temperatures of below approximately 36°C, preferably at room temperature. As appropriate, the process is carried out with cooling and/or under an inert gas atmosphere, for example a nitrogen or argon atmosphere. The resulting liposomes are stable in aqueous phase over a very long period (up to several weeks or months).
The size of the liposomes formed depends inter alia upon the amount of active ingredient and the lipid components, the mixing ratio thereof and the concentration of the components in the aqueous dispersion and upon the method of preparation. For example, by increasing or reducing the concentration of lipid components it is possible to produce aqueous phases having a high proportion of small or large liposomes.
It is possible to obtain an especially uniform size distribution of the liposomes by aftertreatment of the liposome dispersion, for example by treatment with ultrasound or extrusion through straight-pored filters (for example Nucleopore~).
The separation and isolation of a fraction of large liposomes from a fraction containing small liposomes, insofar as it is at all necessary, is effected by means of conventional separation methods, for example gel filtration, for example with Sepharose~ 4B
or Sephacryl~ (Pharmacia SE) as carrier, or by sedimentation of the liposomes in an ultracentrifuge, for example with a gravitational field of 160,000 x g. For example, after centrifugation for several hours, for example about three hours, in that gravitational field,large liposomes are deposited, whereas small liposomes remain in dispersion and can be decanted. Repeated centrifugation results in complete separation of the large liposomes from the small liposomes.
Gel filtration especially can be used to separate off all the liposomes present in the aqueous phase having a diameter of more than about 6.0 x 10-s m and also non-encapsulated components and excess, dispersed lipids that are present in high molecular weight aggregates and thus to produce an aqueous dispersion having a fraction of liposomes of relatively uniform size.
The completed formation of liposomes and their content in aqueous phase can be demonstrated in a manner known Rer se by various physical measuring methods, for example with freeze fracture samples and thin sections under an electron microscope or by X-ray diffraction, by dynamic light scattering, by mass determination of the filtrate in an analytical ultracentrifuge and especially by spectroscopy, for example in the nuclear resonance spectrum (1H, 13C and 3tP).
The present invention relates also to a novel, inventive process for the preparation of a pharmaceutical composition in the form of a dry preparation, which process comprises dissolving a) the zinc-phthalocyanine complex and b) a synthetic, substantially pure phospholipid of formula I, whereim Rt, R2, Ra, Rb and R~
and also n are as defined above, optionally combined with a c) synthetic, substantially pure phospholipid of formula II, wherein R3, R4, n and 'lr~ are as defined above, in a pharmaceutically acceptable organic solvent, the residual amount of which in a dry preparation is toxicologically harmless, and optionally d) adding carrier liquid and water-soluble excipients suitable for parenteral dosage forms, and removing the solvent or solvent mixture.
A pharmaceutically acceptable organic solvent, the residual amount of which in a dry preptrration is toxicologically harmless, is suitable for the preparation of a clear solution of the zinc-phthalocyanine complex and if possible the phospholipid components (I) and (II).
If the phospholipids are insoluble in the organic solvent in which the zinc-phthalocyanine complex is soluble, they are dissolved in a second solvent, for example in tort-butanol, and that solution is combined with the solution of the zinc-phthalocyanine complex.
Preferred organic solvents that meet the toxicological requirements as regards the residual amounts present in the dry preparation and in which the zinc-phthalocyanine complex is soluble are dimethyl sulfoxide, N-methyl-2-pyrrolidone and piperidine, and mixtures thereof.
The zinc-phthalocyanine complex is soluble in dimethyl sulfoxide and N-methyl-2-pyrrolidone (NMP) but the phospholipids (I) and (II) are not. Both the zinc-phthalocyanine complex and the phospholipids (I) and (II) are soluble in piperidine. All solvents are toxicologically harmless in the residual amounts of less than 1 %, preferably less than 0.5 °lo, present in the dry preparation.
When dimethyl sulfoxide or NMP is used, the zinc-phthalocyanine complex is dissolved in the minimum necessary amount of that solvent and the solution is combined with a second solution of the phospholipids that is miscible with the first solution of the zinc-phthalocyanine complex. In addition to the requirement of being miscible with the dimethyl sulfoxide solution, this second solvent is subject to the same toxicological requirements as regards the residual amounts present in the dry preparation.
Such a suitable solvent in which the phospholipids (I) and (1I) are completely soluble is,,for example, tert-butanol.
The preparation of the dry preparation, preferably a lyophilisate, can be effected by modifying known methods, by first dissolving the introduced amount of the phospholipid, for example 1-hexadecanoyl-2-(9-cis-octadecenoyl)-3-sn-phosphatidyl choline, if required with gentle heating, in the amount of tert-butanol required for the dissolution process and combining that clear solution with a second solution comprising a defined amount of the zinc-phthalocyanine complex in an amount of dimethyl sulfoxide or NMP
appropriate for the dissolution process. Alternatively, it is possible to dissolve the phospholipids (I) and (II) at approximately from 0°C to roam temperature, preferably at 0°C, and the zinc-phthalocyanine complex at from room temperature to approximately 40°C, preferably room temperature, in the minimum necessary amount of piperidine or in piperidine containing up to about 10 %, preferably abaut 2 to 3 %, water and to remove the solvent from that clear solution in order to produce the dry preparation. The clear solution in the said organic solvents can then be combined with the carrier liquid d) comprising water-soluble excipients, especially non-ionic additives such as lactose. The dry preparation can be prepared by removing the solvent mixture at low temperature below about 0°C (lyophilisation) or at normal or elevated temperature (film formation). The solvent mixture used for the preparation of the dry preparation can also be dialysed for the purpose of purification and the dialysed aqueous solution, which contains no organic solvent, concentrated by ultrafiltration. The dry preparation is then prepared by removing water, preferably by lyophilisation. Measured amounts of the solution to be lyophilised can be introduced into suitable containers for a unit dose, such as ampoules, for example glass phials. The filled containers can then be frozen at about -40° to -50°C, especially at -45°C, and then lyophilised at a pressure of about 0.2-0.6 mbar by slowly heating to a final temperature of about 25°-35°C.
The solvent or solvent mixture comprising components a), b) and c) can be converted into a dry preparation also directly, without cooling, thermally in a larger vessel (film formation method). Freeze-drying from small vessels containing a unit dose is preferred, however, as this method avoids the operation of filling the dry preparation itself and therefore allows the accurate apportionment of unit doses from liquids.
Surprisingly, it has been possible using the said processes to prepare, reproducibly, dry preparations, especially lyophilisates, and liposome dispersions reconstitutable therefrom, that are st<lble and suitable for injection.
The present invention relates also to the use of the dry preparation obtainable in accordance with the said processes for the preparation of intravenously administrable liposome dispersions.
The present invention relates also to the use of the zinc-phthalocyanine complex and the phospholipid components of formula I and optionally of formula II for the preparation of dry preparations, especially lyophilisates, in accordance with the methods described hereinabove. The invention relates also to the use of the pharmaceutical compositions in a method for the therapeutic treatment of the human or animal body, especially in chemotherapy for the treatment of tumours. The liposome dispersion is administered parenterally, especially intravenously, and the carcinoma is irradiated with high-energy light, preferably with concentrated visible light (LASER).
The invention relates preferably to pharmaceutical compositions in the form of intravenously administrable liposome dispersions comprising a) the zinc-phthalocyanine complex, b) a synthetic, substantially pure phospholipid of formula I, wherein R1 is n-dodecanoyl, n-tetradecanoyl, n-hexadecanoyl or n-octadecanoyl and R2 is 9-cis-dodecenoyl, 9-cis-tetradecenoyl, 9-cis-hexadecenoyl, 9-cis-octadecenoyl or 9-cis-icosenoyl, Ra, Rb and R
are methyl and n is two, optionally combined with a c) synthetic, substantially pure phospholipid of formula II, wherein R3 and R4 are identical and are 9-cis-dodecenoyl, 9-cis-tetradecenoyl, 9-cis-hexadecenoyl, 9-cis-octadecenoyl or 9-cis-icosenoyl, n is one and Y~ is the sodium ion, and d) a pharmaceutically acceptable carrier liquid and, optionally, water-soluble excipients suitable for intravenous dosage forms.
The invention relates preferably also to pharmaceutical compositions in the form of dry preparations comprising the said preferred components a), b), optionally combined with c), and d) water-soluble excipients suitable for intravenous dosage forms.
The invention relates especially to pharmaceutical compositions in the form of intravenously administrable liposome dispersions comprising a) the zinc-phthalocyanine complex, b) synthetic, substantially pure 1-n-hexadecanoyl-2-(9-cis-octadecenoyl)-3-sn-phosphatidyl choline (I), optionally combined with c) synthetic, substantially pure sodium 1,2-di(9-cis-octadecenoyl)-3-sn-phosphatidyl S-serine (II), and d) a pharmaceutically acceptable carrier liquid and, optionally, water-soluble excipients suitable for intravenous dosage forms.
The invention relates especially preferably to pharmaceutical compositions in the form of lyophilisates comprising a) the zinc-phthalocyanine complex, b) synthetic, substantially pure 1-n-hexadecanoyl-2-(9-cis-octadecenoyl)-3-sn-phosphatidyl choline (I), optionally combined with c) synthetic, substantially pure sodium 1,2-di(9-cis-octadecenoyl)-3-sn-phosphatidyl S-serine (II), and d) water-soluble excipients suitable for intravenous dosage forms.
~03~4~'~
The invention relates especially to pharmaceutical compositions in the form of intravenously administrable liposome dispersions comprising a) the zinc-phthalocyanine complex, b) approximately 70 °l° by weight (based on component c)) synthetic, substantially pure 1-n-hexadecanoyl-2-(9-cis-octadecenoyl)-3-sn-phosphatidyl choline (I), combined with c) approximately 30 % by weight (based on component b)) synthetic, substantially pure sodium 1,2-di(9-cis-octadecenoyl)-3-sn-phosphatidyl S-serine (II), and d) a pharmaceutically acceptable carrier liquid and, optionally, water-soluble excipients suitable for intravenous dosage forms.
The invention .relates especially also to pharmaceutical compositions in the form of lyophilisates comprising:
a) the zinc-phthalocyanine complex, b) approximately 70 °l° by weight (based on component c)) synthetic, substantially pure 1-n-hexadecanoyl-2-(9-cis-octadecenoyl)-3-sn-phosphatidyl choline (I), combined with c) approximately 30 °l° by weight (based on component b)) synthetic, substantially pure sodium 1,2-di(9-cis-actadecenoyl)-3-sn-phosphatidyl S-serine (II), and d) water-soluble excipients suitable for intravenous dosage forms.
The following Examples illustrate the invention.
Exam-ale 1: 1 mg of zinc-phthalocyanine, 70 mg of at least 95 °lo pure 1-n-hexadecanoyl-2-(9-cis-octadecenoyl)-3-sn-phosphatidyl choline and 30 mg of at least 95 °l° pure 1,2-di-(9-cis-octadecenoyl)-3-sn-phasphatidyl serine are dissolved in 2 ml of piperidine in a round-bottomed flask. The solution is sterile-filtered using an ACRODISC
membrane filter (2.2 x 10-~ m) and the clear solution is introduced into phials.
After the solution has been frozen at -40°C, the phials are dried in vacuo until a temperature of 25°C has been reached and are sealed under an argon atmosphere.
Before use, 1.5 ml of sterile, calcium- and magnesium-free, phosphate-buffered (pI-I
7.2-7.4) sodium chloride solution (Dulbecco) are introduced into the above-mentioned dry preparation (lyophilisate) at room temperature using a sterile syringe and the phials are shaken for one minute on a standard laboratory shaker (Vortex, stage 7). The resulting liposome dispersion can be stored at 4°C and is suitable for intravenous administration.
Example 2: Depending upon the batch, from 0.1 to 1 mg of zinc-phthalocyanine and from 15 to 400 mg of a 7:3 mixture by weight of 95 to 100 % pure 1-n-hexadecanoyl-2-(9-cis-octadecenoyl)-3-sn-phosphatidyl choline and 95 to 100 % pure 1,2-di(9-cis-octadecenoyl)-3-sn-phosphatidyl serine are dissolved in 2 ml of piperidine in a round-bottomed flask. The solution is sterile-filtered using an ACRODISC
membrane filter (2.2 x 10-~) and the clear solution is introduced into phials.
The phials are set in rotation at 150 rpm and the solvent is blown off in a stream of purified nitrogen filtered at 1 bar.
The phials are then evacuated in a vacuum of 6.0 x 10-2 bar. The phials are sealed under an argon atmosphere. Before use, 1.5 ml of sterile, calcium- and magnesium-free, phosphate-buffered (pH 7.2-7.4) sodium chloride solution (Dulbecco) are added to the above-prepared film at room temperature using a syringe and the phials are shaken for 10 minutes on a standard laboratory shaker (stage 7). The resulting liposome dispersion can be stored at 4°C and is suitable for intravenous administration.
Example 3: In a manner analogous to Example 1, after being frozen the solutions mentioned in Example 2 are dried in vacuo and lyophilisates are prepared.
Example 4: In a manner analogous to Examples 2 and 3 it is also possible to prepare solutions comprising from 5:5 to 9:1 mixtures by weight of 1-n-hexadecanoyl-2-(9-cis-octadecenoyl)-3-sn-phosphatidyl choline and 1,2-di(9-cis-octadecenoyl)-phosphatidyl serine.
Example 5: 125 ml of 95 % pure 1-n-hexadecanoyl-2-(9-cis-octadecenoyl)-3-sn-phosphatidyl choline (Avanti, Polar Lipids) are dissolved in 0.5 ml of tert-butanol in a round-bottomed flask. 0.05 mg of zinc-phthalocyanine is dissolved separately in 0.5 ml of sterile dimethyl sulfoxide in a second round-bottomed flask.
The two solutions are combined and sterile-filtered through an ACRODISC
membrane filter (2.2 x 10-~ m). After the introduction of the clear solution into a phial, it is frozen at -80°C. The phials are dried ip vacuo until a temperature of 25°C
has been reached and are sealed under an argon atmosphere.
The further process steps are carried out analogously to Example 1.
Example 6: 12.5 to 25 mg of 95 °lo pure 1-n-hexadecanoyl-2-(9-cis-octadecenoyl)-3-sn-phosphatidyl choline (Avanti, Folar Lipids) are dissolved in 0.5 ml of tert-butanol in a round-bottomed flask. 0.05 mg of zinc-phthalocyanine is dissolved separately in 0.5 ml of sterile dimethyl sulfoxide in a second round-bottomed flask.
Analogously to Example S the two solutions are combined, sterile-filtered using an ACRODISC and introduced into phials. The phials are set in rotation at 150 rpm and the solvent is blown aff in a stream of purified nitrogen filtered at 1 bar. The phials are then evacuated under a pure vacuum of 6.0 x 10-2 bar. The phials are sealed under a protective argon atmosphere.
The further process steps are carried out analogously to Example 2.
Example 7: 0.5 mg of zinc-phthalocyanine and 250 mg of 95 °lo pure 1-n-hexadecenoyl-2-(9-cis-octadecanoyl)-3-sn-phosphatidyl choline are dissolved in 1 ml of sterile piperidine in a round-bottomed flask. The solution is sterile-filtered using an ACRODISC
membrane filter (2.2 x 10-7 m) and the clear solution is introduced into phials.
Analogously to Example 5 it is possible to produce a lyophilisate or, if desired, a film residue analogously to Example 6, which is then converted into an intravenously administrable liposome dispersion analogously to Example 1 or 2.
Example $: In a manner analogous to Example 7 it is possible to produce a lyophilisate or a film residue by dissolving 3 mg of zinc-phthalocyanine in 1 ml of sterile piperidine.
From these dry preparations there is then produced an intravenously administrable lipasome dispersion analogously to Example 1 or 2.
Example 9: In a measuring flask at room temperature, depending upon the batch 200-400 mg of zinc-phthalocyanine are dissolved in 400 ml of piperidine puriss. and the solution is made up to 500 ml. In a second flask at room temperature, depending upon the batch 120-240 mg of a 7:3 mixture by weight of 95-100 °!o pure 1-n-hexadecanoyl-2-(9-cis-octadecenoyl)-3-sn-phosphatidyl choline and 95-100 % pure 1,2-di(9-cis-octadecenoyl)-3-sn-phosphatidyl S-serine are dissolved in 6 ml of piperidine puriss., and 6-12 ml of the above zinc-phthalocyanine solution are added. The resulting solution is ~~3~4'~~
sterile-filtered using an ACRODISC membrane filter (2.2 x 10-~) and the clear solution is introduced into phials.
The further process steps are carried aut analogously to Example 1.
Example 10: In a measuring flask at room temperature, depending upon the batch 200-400 mg of zinc-phthalocyanine are dissolved in 400 ml of piperidine puriss. and the solution is made up to 500 ml. In a second flask, depending upon the batch 120-240 mg' of a 7:3 mixture by weight.of 95-100 % pure 1-n-hexadecanoyl-2-(9-cis-octadecenoyl)-3-sn-phosphatidyl choline and 95-100 % pure 1,2-di(9-cis-octadecenoyl)-3-sn-phosphatidyl S-serine are dissolved in 6 ml of a piperidine/water mixture (2-10 %) at 0-4°C and at that temperature 6-12 ml of the above zinc-phthalocyanine solution are added dropwise thereto. The resulting solution is sterile-filtered using an ACRODISC
membrane filter (2.2 x 10- ) and the clear solution is introduced into phials.
The further process steps are carried out analogously to Example 2.
Example 11: After sterile-filtration, a solution of zinc-phthalocyanine and lipid mixture prepared according to Example 9 or Example 10 is not introduced into phials but is lyophilised in a batch process. Aliquot amounts of the resulting lyophilisate are converted into a liposome dispersion analogously to Example 1.
Example 12: 100 mg of zinc-phthalocyanine, 7000 mg of 95 % pure 1-n-hexadecanoyl-2-(9-cis-octadecanoyl)-3-sn-phosphatidyl choline (POPC) and 3000 mg of 95 % pure sodium 1,2-di(9-cis-octadecanoyl)-3-sn-phosphatidyl S-serine (OOPS) are dissolved in 205 ml of freshly distilled piperidine in a round-bottomed flask.
To that solution there are added, with stirring, 2000 ml of 9.75 % W/V aqueous lactose solution. After the pII value has been adjusted to 7.0 by the addition of dilute HCl, the resulting dispersion is concentrated to a concentration of 0.5 mg of zinc-phthalocyanine/ml and dialysed against 2000 ml of 9.75 % lactose using a Millipore Minitan~ tangential dialysis apparatus.
The resulting lactose-containing dispersion is then sterile-filtered using an ACRODISC
membrane filter (2.2 x 10- ) and introduced into phials (2 ml per phial containing 1 mg of zinc-phthalocyanine). After the dispersion has been frozen at -4U°C, the phials are dried in vacuo until a temperature of 25°C has been reached and are sealed under an argon atmosphere.
The resulting dry preparations can be stored at 4°C for several years.
Before administration, 2.0 ml of water are injected using a sterile syringe into a dry preparation (lyophilisate) in a phial at room temperature. After a maximum dissolution time of one minute there is formed a liposome dispersion suitable fox intravenous administration.
Example 13: In a manner analogous to Example 12, it is possible to carry out the process with 10 000 mg of POPC.
Example 14: In a manner analogous to Example 13, it is possible to carry out the process with 300 mg of POPC or 210 mg of POPC and 90 mg of OOPS.
Example 15: In a flask, 35 g of POPC and 15 g of OOPS are dissolved in 500 ml of tertiary butanol, with stirring, at 40°C. In a further flask, 0.'i g of zinc-phthalocyanine is dissolved in 125 ml of NMP (ultrasonic bath).
The two solutions are mixed together, the dye solution being poured into the tertiary butanol solution. The mixture is heated to 40°C in order to obtain a clear solution. Using a dynamic mixer, that solution is mixed with 10 litres of lactose medium that has been cooled to 4°C and that contains per litre 94.9 g of lactose for injection and 24 g of sodium chloride.
The organic phase is pumped at a rate of 107 ml/min and the lactose solution at a rate of 1714 ml/min into the dynamic mixer, which is operated at a pressure of 3 bar.
The resulting blue, slightly opalescent dispersion (10625 ml) is concentrated to 1 litre and then dialysed against 10 litres of lactose medium using a Millipore tmgential dialysis .
apparatus.
The further procedure is described in Example 12.
Example 16: In a manner analogous to Example 15, 3.5 g of POPC and 1.5 g of OOPS are dissolved in 100 ml of tort-butanol and mixed with 25 ml of NMP and 100 mg of zinc-phthalocyanine. The organic phase is then mixed with 2 litres of lactose medium (25 g of lactose and 0.064 g of NaCI per litre). The dialysis medium has the same composition.
Example 17: In a manner analogous to Example 16; the organic phase is mixed with 2 litres of lactose medium containing 50 g of lactose and 0.127 g of NaCl per litre.
Example 18: In a manner analogous to Example 15, I0.5 g of POPC and 4.5 g of OOPS' are dissolved in 200 ml of tort-butanol and mixed with 50 ml of NMP containing 200 mg of zinc-phthalocyanine. The organic phase is mixed with 4 litres of lactose medium containing 37.5 g of lactose and 0.095 g of NaCI per litre. The dialysis medium has the same composition.
Exam 1p a 19: In a manner analogous to Example 18, the organic phase is mixed with 4 litres of lactose solution containing 75 g of lactose and 0.1905 g of NaCI
per litre. The dialysis medium has the same composition.
Example 20: In a manner analogous to Example 15, 3.5 g of POPC and 1.5 g of OOPS are dissolved in 200 ml of tert-butanol and mixed with 50 m1 of NMP containing 200 mg of zinc-phthalocyanine. The organic phase is mixed with 4 litres of lactose medium containing 25 g of lactose and 0.064 g of NaCI per litre. The dialysis medium has the same composition.
Claims (28)
1. A pharmaceutical composition in the form of a parenterally administrable liposome dispersion comprising (a) a zinc-phthalocyanine complex of formula (b) a synthetic, substantially pure phospholipid of formula (I) wherein R1 is C10-C20alkanoyl having an even number of carbon atoms, R2 is C10-C20alkenoyl having an even number of carbon atoms, R a, R b and R c are hydrogen or C1-C4alkyl and n is an integer from two to four, and (d) a pharmaceutically acceptable carrier liquid.
2. A pharmaceutical composition according to claim 1, wherein the phospholipid of formula (I) is combined with (c) a synthetic, substantially pure phospholipid of formula (II) wherein R3 and R4 are each independently of the other C10-C20alkanoyl having an even number of carbon atoms, n is an integer from one to three and Y+ is the cation of a pharmaceutically acceptable base.
3. A pharmaceutical composition according to claim 1 or 2, further comprising a water-soluble excipient suitable for parenteral dosage forms.
4. A pharmaceutical composition in the form of an intravenously administrable liposome dispersion comprising (a) a zinc-phthalocyanine complex of formula (b) a synthetic, substantially pure phospholipid of formula (I) wherein R1 is n-dodecanoyl, n-tetradecanoyl, n-hexadecanoyl or n-octadecanoyl, and R2 is 9-cis-dodecenoyl, 9-cis-tetradecenoyl, 9-cis-hexadecenoyl, 9-cis-octadecenoyl or 9-cis-icosenoyl, R a, R b and R c are methyl and n is two, and (d) a pharmaceutically acceptable carrier liquid.
5. A pharmaceutical composition according to claim 4, wherein the phospholipid of formula (I) is combined with (c) a synthetic, substantially pure phospholipid of formula (II) wherein R3 and R4 are identical and are 9-cis-dodecenoyl, 9-cis-tetradecenoyl, 9-cis-hexadecenoyl, 9-cis-octadecenoyl or 9-cis-icosenoyl, n is one and Y+ is a sodium ion.
6. A pharmaceutical composition according to claim 4 or 5, further comprising a water-soluble excipient suitable for intravenous dosage forms.
7. A pharmaceutical composition in the form of an intravenously administrable liposome dispersion comprising (a) a zinc-phthalocyanine complex of formula (b) synthetic, substantially pure 1-n-hexadecanoyl-2-(9-cis-octadecenoyl)-3-sn-phosphatidyl choline, and (d) a pharmaceutically acceptable carrier liquid.
8. A pharmaceutical composition according to claim 7, wherein component (b) is combined with (c) synthetic, substantially pure sodium 1,2-di(9-cis-octadecenoyl)-3-sn-phosphatidyl S-serine.
9. A pharmaceutical composition according to claim 7 or 8, further comprising a water-soluble excipient suitable for intravenous dosage forms.
10. A pharmaceutical composition in the form of an intravenously administrable liposome dispersion comprising (a) a zinc-phthalocyanine complex of formula (b) about 70% by weight (based on component (c)) of synthetic, substantially pure 1-n-hexadecanoyl-2-(9-cis-octadecenoyl)-3-sn-phosphatidyl choline, combined with (c) about 30% by weight (based on component (b)) of synthetic, substantially pure sodium 1,2-di(9-cis-octadecenoyl)-3-sn-phosphatidyl S-serine, and (d) a pharmaceutically acceptable carrier liquid.
11. A pharmaceutical composition according to claim 10, further comprising a water-soluble excipient suitable for intravenous dosage forms.
12. A pharmaceutical composition in the form of a dry preparation comprising (a) a zinc-phthalocyanine complex of formula (b) a synthetic, substantially pure phospholipid of formula (I) as defined in claim 1, wherein R1, R2, R a, R b, R c and n are as defined in claim 1.
13. A pharmaceutical composition according to claim 12, wherein component (b) is combined with (c) a synthetic, substantially pure phospholipid of formula (II) as defined in claim 2, wherein R3, R4, n and Y+ are as defined in claim 2.
14. A pharmaceutical composition according to claim 12 or 13, further comprising a water-soluble excipient suitable for intravenous dosage forms.
15. A pharmaceutical composition in the form of a lyophilisate comprising (a) a zinc-phthalocyanine complex of formula (b) about 70% by weight (based on component (c)) of synthetic, substantially pure 1-n-hexadecanoyl-2-(9-cis-octadecenoyl)-3-sn-phosphatidyl choline, combined with (c) about 30% by weight (based on component (b)) of synthetic, substantially pure sodium 1,2-di(9-cis-octadecenoyl)-3-sn-phosphatidyl S-serine, and (d) a water-soluble excipient suitable for intravenous dosage forms.
16. A process for preparing a pharmaceutical composition in the form of a parenterally administrable liposome dispersion, which process comprises dispersing in aqueous phase a dry preparation comprising (a) a zinc-phthalocyanine complex of formula (b) a synthetic, substantially pure phospholipid of formula (I) as defined in claim 1, wherein R1, R2, R a, R b, R c and n are as defined in claim 1.
17. A process according to claim 16, wherein component (b) is combined with (c) a synthetic, substantially pure phospholipid of formula (II) as defined in claim 2, wherein R3, R4, n and Y+ are as defined in claim 2.
18. A process according to claim 16 or 17, further comprising dispersing water-soluble excipients suitable for parenteral dosage forms.
19. A process according to any one of claims 16 to 18, further comprising buffering the resulting aqueous dispersion to pH 7.0-7.8 and/or isolating a liposome fraction having a desired diameter range.
20. A process for preparing a pharmaceutical composition in the form of a dry preparation, which process comprises dissolving (a) a zinc-phthalocyanine complex of formula (b) a synthetic, substantially pure phospholipid of formula (I) as defined in claim 1, wherein R1, R2, R a, R b, R c and n are as defined in claim 1, in an organic solvent or solvent mixture, a residual amount of which solvent or solvent mixture in a dry preparation is toxicologically harmless, and removing the solvent or solvent mixture.
21. A process according to claim 20, wherein, prior to removing the solvent or solvent mixture, component (b) is combined with (c) a synthetic, substantially pure phospholipid of formula (II) as defined in claim 2, wherein R3, R4, n and Y+ are as defined in claim 2.
22. A process according to claim 20 or 21, further comprising adding a carrier liquid and a water-soluble excipient suitable for parenteral dosage forms prior to removing the solvent or solvent mixture.
23. A process according to any one of claims 20 to 22, wherein the organic solvent is piperidine.
24. The use of a pharmaceutical composition according to any one of claims 12 to 15 for preparing a parenterally administrable liposome dispersion.
25. The use of a zinc-phthalocyanine complex as defined in claim 1 and a phospholipid of formula (I) as defined in claim 1 for preparing a dry preparation.
26. The use according to claim 25, further comprising the use of a phospholipid of formula (II) as defined in claim 2.
27. Use of a pharmaceutical composition according to any one of claims 1 to 15 for treating tumors in a mammal.
28. Use according to claim 27, wherein the mammal is human.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH1104/90-2 | 1990-04-03 | ||
| CH110490 | 1990-04-03 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2039477A1 CA2039477A1 (en) | 1991-10-04 |
| CA2039477C true CA2039477C (en) | 2002-09-24 |
Family
ID=4202574
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002039477A Expired - Fee Related CA2039477C (en) | 1990-04-03 | 1991-03-28 | Parenterally administrable liposome formulation comprising synthetic lipids |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP0451103B1 (en) |
| JP (1) | JPH085793B2 (en) |
| KR (1) | KR910018014A (en) |
| AT (1) | ATE108328T1 (en) |
| AU (1) | AU634644B2 (en) |
| CA (1) | CA2039477C (en) |
| DE (1) | DE59102143D1 (en) |
| DK (1) | DK0451103T3 (en) |
| ES (1) | ES2056617T3 (en) |
| FI (1) | FI104951B (en) |
| HU (1) | HU208485B (en) |
| IE (1) | IE64990B1 (en) |
| IL (1) | IL97681A (en) |
| NO (1) | NO302735B1 (en) |
| NZ (1) | NZ237631A (en) |
| PH (1) | PH30330A (en) |
| PT (1) | PT97215B (en) |
| ZA (1) | ZA912425B (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6890555B1 (en) | 1992-02-05 | 2005-05-10 | Qlt, Inc. | Liposome compositions of porphyrin photosensitizers |
| CA2087902C (en) * | 1992-02-05 | 2006-10-17 | Narendra Raghunathji Desai | Liposome compositions of porphyrin photosensitizers |
| TW235298B (en) * | 1992-02-27 | 1994-12-01 | Ciba Geigy | |
| US5616602A (en) * | 1993-07-09 | 1997-04-01 | Ciba-Geigy Corporation | Topically administrable zinc phthalocyanine compositions |
| WO1997010811A1 (en) * | 1995-09-21 | 1997-03-27 | Novartis Ag | Nanoparticles in photodynamic therapy |
| US5715023A (en) * | 1996-04-30 | 1998-02-03 | Kaiser Electro-Optics, Inc. | Plane parallel optical collimating device employing a cholesteric liquid crystal |
| US6010890A (en) * | 1997-04-29 | 2000-01-04 | New York Blood Center, Inc. | Method for viral inactivation and compositions for use in same |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1260393A (en) * | 1984-10-16 | 1989-09-26 | Lajos Tarcsay | Liposomes of synthetic lipids |
| EP0358640B1 (en) * | 1987-02-23 | 1992-09-16 | Vestar, Inc. | Dehydrating vesicule preparations for long-term storage |
-
1991
- 1991-03-26 DK DK91810217.9T patent/DK0451103T3/en active
- 1991-03-26 EP EP91810217A patent/EP0451103B1/en not_active Expired - Lifetime
- 1991-03-26 IL IL9768191A patent/IL97681A/en not_active IP Right Cessation
- 1991-03-26 ES ES91810217T patent/ES2056617T3/en not_active Expired - Lifetime
- 1991-03-26 AT AT91810217T patent/ATE108328T1/en not_active IP Right Cessation
- 1991-03-26 DE DE59102143T patent/DE59102143D1/en not_active Expired - Fee Related
- 1991-03-27 PH PH42213A patent/PH30330A/en unknown
- 1991-03-27 FI FI911501A patent/FI104951B/en not_active IP Right Cessation
- 1991-03-28 IE IE107691A patent/IE64990B1/en not_active IP Right Cessation
- 1991-03-28 NZ NZ237631A patent/NZ237631A/en unknown
- 1991-03-28 CA CA002039477A patent/CA2039477C/en not_active Expired - Fee Related
- 1991-04-01 PT PT97215A patent/PT97215B/en not_active IP Right Cessation
- 1991-04-02 ZA ZA912425A patent/ZA912425B/en unknown
- 1991-04-02 JP JP3069856A patent/JPH085793B2/en not_active Expired - Fee Related
- 1991-04-02 HU HU911070A patent/HU208485B/en not_active IP Right Cessation
- 1991-04-02 AU AU74046/91A patent/AU634644B2/en not_active Ceased
- 1991-04-02 KR KR1019910005252A patent/KR910018014A/en not_active Application Discontinuation
- 1991-04-02 NO NO911281A patent/NO302735B1/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| NZ237631A (en) | 1992-12-23 |
| EP0451103B1 (en) | 1994-07-13 |
| ZA912425B (en) | 1991-11-27 |
| NO302735B1 (en) | 1998-04-20 |
| HU911070D0 (en) | 1991-10-28 |
| PT97215B (en) | 1998-07-31 |
| PH30330A (en) | 1997-04-02 |
| AU634644B2 (en) | 1993-02-25 |
| HU208485B (en) | 1993-11-29 |
| IE911076A1 (en) | 1991-10-09 |
| AU7404691A (en) | 1991-10-10 |
| FI104951B (en) | 2000-05-15 |
| IE64990B1 (en) | 1995-09-20 |
| FI911501A (en) | 1991-10-04 |
| HUT59009A (en) | 1992-04-28 |
| CA2039477A1 (en) | 1991-10-04 |
| KR910018014A (en) | 1991-11-30 |
| IL97681A0 (en) | 1992-06-21 |
| NO911281L (en) | 1991-10-04 |
| ATE108328T1 (en) | 1994-07-15 |
| JPH04221316A (en) | 1992-08-11 |
| JPH085793B2 (en) | 1996-01-24 |
| FI911501A0 (en) | 1991-03-27 |
| DE59102143D1 (en) | 1994-08-18 |
| NO911281D0 (en) | 1991-04-02 |
| EP0451103A1 (en) | 1991-10-09 |
| ES2056617T3 (en) | 1994-10-01 |
| IL97681A (en) | 1996-01-31 |
| PT97215A (en) | 1992-01-31 |
| DK0451103T3 (en) | 1994-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5466468A (en) | Parenterally administrable liposome formulation comprising synthetic lipids | |
| US5270053A (en) | Parenterally administerable liposome formulation comprising synthetic lipid | |
| FI86371C (en) | FOERFARANDE FOER FRAMSTAELLNING AV FARMACEUTISKA LIPOSOMKOMPOSITIONER. | |
| KR890004689B1 (en) | Compositions consisting of phospholipid encapsulated anthracyline anti-neoplastic agents | |
| ES2272496T3 (en) | DEHYDRATION / REHIDRITATION PROCEDURE FOR THE PREPARATION OF LIPOSOSMS. | |
| JP3782112B2 (en) | Method for making liposomes containing hydro-monobenzoporphyrin photosensitizer | |
| EP0303683B1 (en) | Amphotericin b/cholesterol sulfate composition and method | |
| CN1044093C (en) | Low-toxicity medicinal lipid preparation | |
| NL8501010A (en) | IMPROVEMENTS OR RELATED TO INTERLEUKIN THERAPY. | |
| WO2004017940A2 (en) | Pharmaceutically active lipid based formulation of sn38 | |
| JPH0534334B2 (en) | ||
| JP2009507049A (en) | Nanomicelle formulation of vinca alkaloid anticancer drug encapsulated in polyethylene glycol derivative of phospholipid | |
| CA2050679C (en) | Preparation of liposome and lipid complex compositions | |
| JP2007522085A (en) | Stabilized topotecan liposome compositions and methods | |
| CA2039477C (en) | Parenterally administrable liposome formulation comprising synthetic lipids | |
| US20060030578A1 (en) | Pharmaceutically active lipid based formulation of irinotecan | |
| CA1273575A (en) | Pharmaceutical compositions consisting of acylated phospholipids | |
| CN101411690B (en) | 2-methoxyestradiol lipidosome freeze-dried injection and preparation method thereof | |
| US20040228911A1 (en) | Vinorelbine compositions and methods of use | |
| CN103040764B (en) | Bleomycin hydrocloride lipidosome injection | |
| CN110575549B (en) | tbFGF ligand-modified liposome with tumor active targeting function and preparation method and application thereof | |
| Gerke et al. | Physicochemical characterization of protein-free low density lipoprotein models and influence of drug loading | |
| CN110643031A (en) | New material containing tbFGF and application thereof | |
| CN115887692A (en) | PEG-modified docetaxel liposome freeze-dried powder and preparation method thereof | |
| JP2002518322A (en) | Busulfan liposome formulation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |